Uniseed is a venture fund operating at the Universities of Melbourne, Queensland and New South Wales, with investment capital provided by the three universities and AustralianSuper – a leading industry superannuation fund. Uniseed’s mandate is to facilitate the commercialisation of university-generated intellectual property by targeted investment in highly promising technologies.
Uniseed’s investments cover a range of technology sectors. To date, the fund has exited three investments through trade sales; a drug in development to treat fibrosis (Fibrotech), an IT security technology (Vintela) and a semi-conductor technology (Fultec). Its biotechnology portfolio is maturing, with QRxPharma having completed a number of Phase 3 trials, Hatchtech completing a pivotal Phase 3 trial for its human head lice treatment in 2014, and two other companies having completed Phase 2 clinical trials with novel therapies for neuropathic pain (Spinifex) and diabetes (Verva). Other companies have products on the market (BT Imaging, Smart Sparrow) or are colaborating with leading global companies in the respective field.